Gülşen Özer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gülşen Özer has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Özge Köprülü
Department of Pediatric Endocrinology University of Health Sciences, Dr. Behçet Uz Children's Hospital İzmir Turkey
2 shared publications - İbrahim Mert Erbaş
Department of Pediatric Endocrinology, University of Health Sciences, İzmir Faculty of Medicine, Dr. Behçet Uz Children’s Hospital, İzmir, Türkiye
2 shared publications Behzat Özkan
Department of Pediatric Endocrinology University of Health Sciences, Dr. Behçet Uz Children's Hospital İzmir Turkey
1 shared publication- Behzat Özkan
Department of Pediatric Endocrinology, University of Health Sciences, İzmir Faculty of Medicine, Dr. Behçet Uz Pediatric Diseases and Surgery Training and Research Hospital, İzmir, Turkey
1 shared publication Fatma Yavuzyılmaz Şimşek
Department of Pediatric Endocrinology University of Health Sciences, Dr. Behçet Uz Children's Hospital İzmir Turkey
1 shared publication- Nagihan Cevher Binici
Department of Child and Adolescent Psychiatry Faculty of Medicine, Dokuz Eylül University İzmir Türkiye
1 shared publication
Latest Publications
- 18 February 2026
- Published by Wiley in Clinical Endocrinology
Quality of Life in Children With Congenital Adrenal Hyperplasia: A Tertiary‐Center Case‐Control Study
Background: Congenital adrenal hyperplasia (CAH) is a chronic endocrine disorder affecting adrenal steroidogenesis, often requiring lifelong glucocorticoid therapy. Its impact on health‐related quality of life (HRQoL) in pediatric patients is inconsistent in the literature, with limited data from specific populations. Objective: To compare HRQoL in children and adolescents with CAH to healthy peers, and to evaluate the influence of age, sex, ambiguous genitalia, and glucocorticoid dose. Methods: This cross‐sectional case‐control study included 25 children and adolescents with CAH (aged 5–18 years) and 25 healthy controls frequency‐matched for age and sex. HRQoL was assessed using the Pediatric Quality of Life Inventory (PedsQL™ 4.0) via child self‐reports and parent proxy reports. Participants were grouped by age: 5–6, 7–12, and 13–18 years. Clinical data, including, presence of ambiguous genitalia, and glucocorticoid dose, were recorded. Results: Overall, HRQoL scores were similar between CAH patients and controls. Age‐stratified analysis showed that children aged 7–12 years with CAH reported higher physical functioning ( p = 0.037) and total HRQoL ( p = 0.04) compared to controls. Adolescents with CAH reported significantly lower school functioning ( p = 0.03), while other domains were comparable. No significant differences in HRQoL were observed by sex, ambiguous genitalia, or glucocorticoid dose. Conclusion: Children and adolescents with CAH generally achieve HRQoL comparable to healthy peers under adequate treatment. Age‐specific differences suggest younger children may experience preserved or enhanced physical well‐being, while adolescents are vulnerable to reduced school functioning. These findings highlight the need for multidisciplinary, age‐sensitive management strategies that include psychological and academic support, especially during adolescence.
- 18 February 2026
- Published by Wiley in Clinical Endocrinology
Quality of Life in Children With Congenital Adrenal Hyperplasia: A Tertiary‐Center Case‐Control Study
Background: Congenital adrenal hyperplasia (CAH) is a chronic endocrine disorder affecting adrenal steroidogenesis, often requiring lifelong glucocorticoid therapy. Its impact on health‐related quality of life (HRQoL) in pediatric patients is inconsistent in the literature, with limited data from specific populations. Objective: To compare HRQoL in children and adolescents with CAH to healthy peers, and to evaluate the influence of age, sex, ambiguous genitalia, and glucocorticoid dose. Methods: This cross‐sectional case‐control study included 25 children and adolescents with CAH (aged 5–18 years) and 25 healthy controls frequency‐matched for age and sex. HRQoL was assessed using the Pediatric Quality of Life Inventory (PedsQL™ 4.0) via child self‐reports and parent proxy reports. Participants were grouped by age: 5–6, 7–12, and 13–18 years. Clinical data, including, presence of ambiguous genitalia, and glucocorticoid dose, were recorded. Results: Overall, HRQoL scores were similar between CAH patients and controls. Age‐stratified analysis showed that children aged 7–12 years with CAH reported higher physical functioning ( p = 0.037) and total HRQoL ( p = 0.04) compared to controls. Adolescents with CAH reported significantly lower school functioning ( p = 0.03), while other domains were comparable. No significant differences in HRQoL were observed by sex, ambiguous genitalia, or glucocorticoid dose. Conclusion: Children and adolescents with CAH generally achieve HRQoL comparable to healthy peers under adequate treatment. Age‐specific differences suggest younger children may experience preserved or enhanced physical well‐being, while adolescents are vulnerable to reduced school functioning. These findings highlight the need for multidisciplinary, age‐sensitive management strategies that include psychological and academic support, especially during adolescence.
- Open Access
- 1 September 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (5) , 483-490
Clinical and Laboratory Characteristics of Patients with Genetic Rickets: A Single-Center Experience with Long-Term Outcomes
Objective: Rickets is a metabolic bone disease characterized by inadequate mineralization of growing bone due to a deficiency of calcium, phosphorus, and vitamin D or defects in their metabolism. This study aimed to evaluate the clinical, laboratory, and molecular characteristics and long-term follow-up of the patients diagnosed with genetic rickets. Materials and Methods: This study is designed as a retrospective case series with genetic rickets. The clinical, laboratory, and molecular characteristics of 16 patients, monitored at the Department of Pediatric Endocrinology in Dr. Behçet Uz Children’s Hospital between 2010 and 2024, were analyzed retrospectively. A questionnaire was used to evaluate all clinical, biochemical data related to the diagnosis, treatment, and long-term follow-up. The characteristics of the patients who reached their final height were analyzed. Results: Sixteen patients were included in the study. Six patients had vitamin D–dependent rickets type 1, 2 had vitamin D–dependent rickets type 2, and 8 had hypophosphatemic rickets (HPR). The most common presentation was leg deformities, followed by delayed walking, growth retardation, and alopecia. The mean age at presentation was 3.5 ± 3.1 years. Physical examination findings included short stature, joint widening, genu varum, and genu valgum. The diagnosis of 14 of the cases was confirmed by demonstration of the variants. The mean followup period for the patients was 6.6 ± 4.75 years. The mean final height of the 4 patients, who reached their final height, was 142.07 ± 11.19 cm. Nephrocalcinosis was observed in 2 patients during follow-up. Conclusion: This study provides valuable insights into the clinical and laboratory characteristics, as well as long-term follow-up outcomes of children with genetic rickets. Cite this article as: Köprülü Ö, Özer G, Erbaş IM, Nalbantoğlu Ö, Gürsoy S, Özkan B. Clinical and laboratory characteristics of patients with genetic rickets: A single-center experience with long-term outcomes. Turk Arch Pediatr. 2025;60(5):483-490.
- 1 September 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (5) , 483-490
Open AccessClinical and Laboratory Characteristics of Patients with Genetic Rickets: A Single-Center Experience with Long-Term Outcomes
Objective: Rickets is a metabolic bone disease characterized by inadequate mineralization of growing bone due to a deficiency of calcium, phosphorus, and vitamin D or defects in their metabolism. This study aimed to evaluate the clinical, laboratory, and molecular characteristics and long-term follow-up of the patients diagnosed with genetic rickets. Materials and Methods: This study is designed as a retrospective case series with genetic rickets. The clinical, laboratory, and molecular characteristics of 16 patients, monitored at the Department of Pediatric Endocrinology in Dr. Behçet Uz Children’s Hospital between 2010 and 2024, were analyzed retrospectively. A questionnaire was used to evaluate all clinical, biochemical data related to the diagnosis, treatment, and long-term follow-up. The characteristics of the patients who reached their final height were analyzed. Results: Sixteen patients were included in the study. Six patients had vitamin D–dependent rickets type 1, 2 had vitamin D–dependent rickets type 2, and 8 had hypophosphatemic rickets (HPR). The most common presentation was leg deformities, followed by delayed walking, growth retardation, and alopecia. The mean age at presentation was 3.5 ± 3.1 years. Physical examination findings included short stature, joint widening, genu varum, and genu valgum. The diagnosis of 14 of the cases was confirmed by demonstration of the variants. The mean followup period for the patients was 6.6 ± 4.75 years. The mean final height of the 4 patients, who reached their final height, was 142.07 ± 11.19 cm. Nephrocalcinosis was observed in 2 patients during follow-up. Conclusion: This study provides valuable insights into the clinical and laboratory characteristics, as well as long-term follow-up outcomes of children with genetic rickets. Cite this article as: Köprülü Ö, Özer G, Erbaş IM, Nalbantoğlu Ö, Gürsoy S, Özkan B. Clinical and laboratory characteristics of patients with genetic rickets: A single-center experience with long-term outcomes. Turk Arch Pediatr. 2025;60(5):483-490.